I found a post from you, ER, back in November stating that someone on Stocktwits was posting lots about Strayhorn - couldn’t find anything else though.

I know plenty of people in the medical community who invest in companies after reading published papers. It certainly will increase interest but I think the real movement starts with interim data. (Amerex judgement/settlement will help too.) I also know many in the medical community who got out of CYDY because of Nader and crew. I think some will consider coming back with published data but most will with clinical trial results. GLTAL